JP4910695B2 - 血栓造影剤 - Google Patents
血栓造影剤 Download PDFInfo
- Publication number
- JP4910695B2 JP4910695B2 JP2006510171A JP2006510171A JP4910695B2 JP 4910695 B2 JP4910695 B2 JP 4910695B2 JP 2006510171 A JP2006510171 A JP 2006510171A JP 2006510171 A JP2006510171 A JP 2006510171A JP 4910695 B2 JP4910695 B2 JP 4910695B2
- Authority
- JP
- Japan
- Prior art keywords
- thrombus
- formula
- group
- compound
- iiia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000007536 Thrombosis Diseases 0.000 title description 53
- 239000002872 contrast media Substances 0.000 title description 24
- 150000001875 compounds Chemical class 0.000 claims description 81
- 230000027455 binding Effects 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 15
- 238000002372 labelling Methods 0.000 claims description 9
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 34
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 29
- 238000000034 method Methods 0.000 description 27
- 238000012360 testing method Methods 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 16
- 125000003545 alkoxy group Chemical group 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- -1 tetrahydroisoquinolyl group Chemical group 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 11
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- 238000001816 cooling Methods 0.000 description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004623 platelet-rich plasma Anatomy 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 229960000711 alprostadil Drugs 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002600 positron emission tomography Methods 0.000 description 6
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 3
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- UMIGTGMFRRGQCV-SNAWJCMRSA-N (e)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]prop-2-enoic acid Chemical compound CC(C)(C)OC(=O)N1CCC(\C=C\C(O)=O)CC1 UMIGTGMFRRGQCV-SNAWJCMRSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000005239 aroylamino group Chemical group 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- PXGLZFRYGYKVFA-CABCVRRESA-N (2s)-2-(methoxycarbonylamino)-3-[[(3r)-1-(3-piperidin-4-ylpropanoyl)piperidine-3-carbonyl]amino]propanoic acid Chemical compound C1[C@H](C(=O)NC[C@H](NC(=O)OC)C(O)=O)CCCN1C(=O)CCC1CCNCC1 PXGLZFRYGYKVFA-CABCVRRESA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- HFKACJIGVWAJRR-GORDUTHDSA-N 2-[2-(carboxymethoxy)-4-[2-[methyl-[(e)-3-piperidin-4-ylprop-2-enoyl]amino]acetyl]phenoxy]acetic acid Chemical compound C1CNCCC1/C=C/C(=O)N(C)CC(=O)C1=CC=C(OCC(O)=O)C(OCC(O)=O)=C1 HFKACJIGVWAJRR-GORDUTHDSA-N 0.000 description 1
- LQMLGFMPVLAXCH-DPZBITMOSA-N 2-[2-(carboxymethoxy)-4-[2-[methyl-[(e)-3-piperidin-4-ylprop-2-enoyl]amino]acetyl]phenoxy]acetic acid;hydrochloride Chemical compound Cl.C1CNCCC1/C=C/C(=O)N(C)CC(=O)C1=CC=C(OCC(O)=O)C(OCC(O)=O)=C1 LQMLGFMPVLAXCH-DPZBITMOSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WRDXQNSYXNZGBE-KATJJAOZSA-N 4-[(E)-3-[[(Z)-2-[3,4-bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]phenyl]-2-[tert-butyl(dimethyl)silyl]oxyethenyl]amino]-3-oxoprop-1-enyl]piperidine-1-carboxylic acid Chemical compound C1=C(OCC(=O)OC(C)(C)C)C(OCC(=O)OC(C)(C)C)=CC=C1C(\O[Si](C)(C)C(C)(C)C)=C\NC(=O)\C=C\C1CCN(C(O)=O)CC1 WRDXQNSYXNZGBE-KATJJAOZSA-N 0.000 description 1
- FBVMSNVEMBYLOQ-GORDUTHDSA-N 4-[(E)-3-[[2-(3,4-dihydroxyphenyl)-2-oxoethyl]-methylamino]-3-oxoprop-1-enyl]piperidine-1-carboxylic acid Chemical compound C1CN(C(O)=O)CCC1/C=C/C(=O)N(C)CC(=O)C1=CC=C(O)C(O)=C1 FBVMSNVEMBYLOQ-GORDUTHDSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- MVXDYARUNWAUEW-KYWSJKHYSA-N CC(C)(C)OC(=O)COC1=C(C=C(C=C1)/C(=C/N([11CH3])C(=O)/C=C/C2CCN(CC2)C(=O)O)/O[Si](C)(C)C(C)(C)C)OCC(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)COC1=C(C=C(C=C1)/C(=C/N([11CH3])C(=O)/C=C/C2CCN(CC2)C(=O)O)/O[Si](C)(C)C(C)(C)C)OCC(=O)OC(C)(C)C MVXDYARUNWAUEW-KYWSJKHYSA-N 0.000 description 1
- GVFGDUKSKBCBFF-UHFFFAOYSA-N CC(O)=O.CC(O)=O.OC(=O)C(F)(F)F Chemical compound CC(O)=O.CC(O)=O.OC(=O)C(F)(F)F GVFGDUKSKBCBFF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OEAYMFALTNRFDD-UHFFFAOYSA-N Cl.C(C)(C)(C)C(C(=O)O)(OC1=C(C=C(C=C1)C(CN)=O)OCC(=O)O)C(C)(C)C Chemical compound Cl.C(C)(C)(C)C(C(=O)O)(OC1=C(C=C(C=C1)C(CN)=O)OCC(=O)O)C(C)(C)C OEAYMFALTNRFDD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- DHVIZBBCXGKXDW-UHFFFAOYSA-N N-(1-bromoethyl)-N-propan-2-ylpropan-2-amine Chemical compound BrC(C)N(C(C)C)C(C)C DHVIZBBCXGKXDW-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 101710099833 Venom protein Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- PZMVOUYYNKPMSI-UHFFFAOYSA-N adrenalone Chemical compound CNCC(=O)C1=CC=C(O)C(O)=C1 PZMVOUYYNKPMSI-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- FPKOGTAFKSLZLD-FQEVSTJZSA-N lamifiban Chemical compound C1=CC(C(=N)N)=CC=C1C(=O)N[C@H](C(=O)N1CCC(CC1)OCC(O)=O)CC1=CC=C(O)C=C1 FPKOGTAFKSLZLD-FQEVSTJZSA-N 0.000 description 1
- 229950003178 lamifiban Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- NMNRAVNMXZIMGY-SDNWHVSQSA-N tert-butyl 4-[(e)-3-[[2-[3,4-bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]phenyl]-2-oxoethyl]-methylamino]-3-oxoprop-1-enyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1/C=C/C(=O)N(C)CC(=O)C1=CC=C(OCC(=O)OC(C)(C)C)C(OCC(=O)OC(C)(C)C)=C1 NMNRAVNMXZIMGY-SDNWHVSQSA-N 0.000 description 1
- GIGGVXDFQZLQRJ-JLHYYAGUSA-N tert-butyl 4-[(e)-3-[[2-[3,4-bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]phenyl]-2-oxoethyl]amino]-3-oxoprop-1-enyl]piperidine-1-carboxylate Chemical compound C1=C(OCC(=O)OC(C)(C)C)C(OCC(=O)OC(C)(C)C)=CC=C1C(=O)CNC(=O)\C=C\C1CCN(C(=O)OC(C)(C)C)CC1 GIGGVXDFQZLQRJ-JLHYYAGUSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Description
すなわち、アデノシンジホスフェート(ADP)誘導血小板凝集阻害試験において、IC50=0.087μMを示す標識したペプチドまたはIC50=0.079μM±0.017μMを示す標識したペプチドを用いて血栓の造影を行い得ることが知られている(非特許文献1および非特許文献2)。また、ADPで活性化した血小板に結合性を示す標識したタンパク質を用いて血栓の造影を行ない得ることも知られている(非特許文献3)。
R2は、カルボキシ基または保護されたカルボキシ基を表し;
A1は、それぞれ1つ以上の置換基を有していてもよい低級アルキレン基、低級アルカニル−イリデン基または低級アルケニレン基を表し;
A2は、低級アルキレン基を表し;
A3は、1つ以上の置換基を有していてもよい低級アルキレン基を表し;
X1は、O、SまたはNHを表し;
Y1は、NHを表し;
Z1は、
m、nおよびpは、同一または異なって、それぞれ、0または1の整数を表す)
で表される化合物、一般式(II):
R5は、カルボキシ基または保護されたカルボキシ基を表し;
A4は、低級アルキレン基、低級アルカニル−イリデン基、低級アルケニレン基、シクロ(低級)アルキレン基またはアリーレン基を表し;
A5は、アリーレン基または1つ以上の置換基を有していてもよい低級アルキレン基を表し;
で表される化合物、一般式(III):
A6は、低級アルキレン基または低級アルケニレン基を表し;
R7は、水素原子;またはアミノ、低級アルカノイルアミノ、アル(低級)アルコキシカルボニルアミノ、アリール、アロイルアミノ、カルボキシ、低級アルコキシカルボニルアミノ、アル(低級)アルコキシ、低級アルコキシカルボニル、低級アルカノイルオキシ、低級アルコキシもしくはヒドロキシ(これらのうち、アリールおよびアロイルアミノはさらにカルボキシ、低級アルコキシもしくは低級アルコキシカルボニルで置換されていてもよい)で置換されていてもよい低級アルカノイル基;低級アルコキシ、アリールもしくはシクロ(低級)アルキルで置換されていてもよい低級アルコキシカルボニル基;低級アルケニルオキシカルボニル基;ジ(低級)アルキルアミノスルホニル基;低級アルコキシで置換されていてもよいシクロアルカノイル基;(C3〜C6)アルコキシ、カルバモイル(低級)アルコキシ、N−(低級)アルキルカルバモイル(低級)アルコキシ、N,N−ジ(低級)アルキルカルバモイル(低級)アルコキシ、低級アルコキシカルボニル、ニトロ、シアノ、カルボキシ、カルボキシ(低級)アルコキシ、アル(低級)アルコキシ、低級アルコキシカルボニル(低級)アルコキシ、シクロ(低級)アルコキシ、低級アルコキシカルボニルアミノ、シクロ(低級)アルキル(低級)アルコキシ、低級アルカノイルアミノもしくは低級アルキルカルバモイルで置換されていてもよいアロイル基;アリールオキシカルボニル基;ヘテロサイクリルカルボニル基;保護されたカルボキシカルボニル基ならびにヘテロサイクリルオキシカルボニル基からなる群から選択されるアシル基で置換されていてもよいアミノ基を表し;R8は、水素原子または1つ以上のヒドロキシおよび/または低級アルコキシで置換されていてもよいアリールもしくはアラルキル基を表し;
式:
で表される化合物等が知られている(特許文献1〜4)。
これらの化合物は、GPIIb/IIIa拮抗剤として血栓形成の予防等に有効であることは知られていたが、血栓造影剤として用い得ることは知られていなかった。
で表される化合物ならびに生理的に許容されるそれらの塩から選択される、GPIIb/IIIa結合性化合物を標識化してなる物質を作用物質として含む血栓造影剤を提供するものである。
本発明は、さらに、上記の血栓造影剤を哺乳動物に投与し、血栓に局在化した標識を検出する工程を含む血栓の検出方法をも提供するものである。
上記GPIIb/IIIa結合性化合物は、血小板表面に産生するGPIIb/IIIaに結合性を有する化合物であればよく、好ましくは、活性型GPIIb/IIIaに選択的に結合性を有する化合物である。このようなGPIIb/IIIa結合性化合物を用いることにより、血栓の主たる構成成分である血小板の膜上に存在する活性型GPIIb/IIIaに特異的に結合し、血流中に存在する静止型GPIIb/IIIaに結合性が低い血栓造影剤を得ることができる。
上記のGPIIb/IIIa結合性化合物は、後記の血小板凝集阻害活性の測定結果およびプロスタグランジンE1(PGE1)処理血小板のフィブリノゲン粘着抑制活性の測定結果を用いて、R/A比を算出することにより、活性型GPIIb/IIIaに対する特異的結合性を判定することができる。
上記の一般式(I)で表される化合物としては、国際公開公報WO95/08536号に記載の化合物を含む。上記の一般式(II)で表される化合物としては、国際公開公報WO96/29309号に記載の化合物を含む。上記の一般式(III)で表される化合物としては、国際公開公報WO97/33869号、国際公開公報WO01/60813号および国際公開公報WO00/21932号に記載の化合物を含む。
従って、上記の一般式(I)〜(III)の化合物の詳細については、ここに参考文献として組み込まれるこれらの特許文献を参照されたい。
因みに、アミノ保護基としては、通常のアミノ保護基を用いることができ、アセチル、プロピオニル等の低級アルカノイル基;ベンゾイル、ナフトイル等のアロイル基;ベンジル、4−ニトロベンジル、フェネチル、1−フェネチル、ベンズヒドリル、トリチル等の置換基を有していてもよいアル(低級)アルキル基;tert−ブチルオキシカルボニル等の低級アルコキシカルボニル基;ベンジルオキシカルボニル、フルオレニルメトキシカルボニル等のアル(低級)アルコキシカルボニル基等が挙げられる。
式(c)の化合物と(d)の化合物との反応は、適切な触媒の存在下で行うことが好ましい。触媒としては、ヨウ化テトラブチルアンモニウム等を用いることができる。
このようにして得られる式(e)の化合物における保護基の脱離は、常法により、例えば化合物(e)を塩酸で処理することにより、化合物(IV)へ導くことができる。
GPIIb/IIIa結合性化合物を標識する方法としては、従来公知の標識方法を用いることができる。例えば11Cにより標識する方法としては、[11C]CH3Iを用いたメチル化方法等を用いることができる。このような方法により、上記の(I)〜(IV)で表される化合物およびそれらの生理的に許容される塩を任意に標識することができる。
本発明の血栓造影剤におけるGPIIb/IIIa結合性化合物の含量は、該血栓造影剤を用いた検出において血栓に局在化した標識を検出できる程度であればよく、用途に応じて適宜選択される。
本発明の血栓造影剤の投与量は、標識化したGPIIb/IIIa結合性化合物を検出する検出器の感度により適宜選択される。例えば、サルでは185〜740MBq程度、ヒトでは185〜740MBq程度となる量で投与することが好ましい。
ジメチルホルムアミド(DMF;2ml)中の式:
1H-NMR (300MHz, CDCl3) δ; 1.33-1.45(2H, m), 1.46(9H, s), 1.70-1.82(2H, m), 2.28-2.46(1H, m), 2.71-2.84(2H, m), 2.91(3H, s), 3.49(2H, brs), 4.06-4.22 (2H, m), 4.78(2H, s), 6.37(1H, d, J=15.8Hz), 6.80(1H, d, J=8.1Hz), 6.92(1H, dd, J=15.8, 7.0Hz), 7.30(1H, d, J=8.1Hz), 7.36(1H, s); MS(ES+) m/z419(M+1)
1H-NMR(300MHz, CDCl3) δ; 1.24-1.51(2H,m), 1.47(9H, s), 1.48(9H, s), 1.49(9H, s), 1.71-1.80(2H, m), 2.26-2.40(1H, m), 2.66-2.84(2H, m), 3.13(3H, s), 4.03-4.20(2H, m), 4.63(2H, s), 4.68(2H, s), 4.82(2H, s), 6.33(1H, d, J=15.0Hz), 6.82(1H, d, J=8.4Hz), 6.89(1H, dd, J=15.0, 8.4Hz), 7.49(1H, s), 7.60(1H, d, J=8.4Hz); MS(ES+) m/z647(M+1)
1H-NMR(300MHz, DMSO-d6) δ; 1.43-2.16(4H, m), 2.80-3.48(7H, m), 3.12(3x0.5H, s), 3.20(3x0.5H, s), 4.87(2H, brs), 4.92-4.99(4H, m), 6.29(1H, brd), 6.57-6.79(1H, m), 7.07-7.19(1H, m), 7.50(1H, brs), 7.72-7.80(1H, m), 8.86-9.13(1H, brs); MS(ES+) m/z435(M+1)
国際公開公報WO01/60813号に記載の方法(実施例19)に従い、上記の式(III−1)の化合物を製造した。
公知の方法に従い、式:
製造例4
公知の方法に従い、式:
製造例5
公知の方法に従い、式:
製造例6
国際公開公報WO01/60813号に記載の方法に従い、式:
製造例7
国際公開公報WO01/60813号に記載の方法に従い、式:
製造例8
国際公開公報WO01/60813号に記載の方法に従い、式:
製造例9
国際公開公報WO01/60813号に記載の方法に従い、式:
製造例10
国際公開公報WO01/60813号に記載の方法に従い、式:
製造例11
国際公開公報WO01/60813号に記載の方法に従い、式:
製造例12
国際公開公報01/60813号に記載の方法に従い、式:
製造例13
国際公開公報WO01/60813号に記載の方法に従い、式:
製造例14
公知の方法に従い、式:
製造例15
公知の方法に従い、式:
製造例16
国際公開公報WO01/60813号に記載の方法に従い、式:
製造例17
国際公開公報WO01/60813号に記載の方法に従い、式:
国際公開公報WO01/60813号に記載の方法に従い、式:
国際公開公報WO01/60813号に記載の方法に従い、式:
国際公開公報WO01/60813号に記載の方法に従い、式:
製造例1〜20で製造した化合物を用いて、以下の試験を行った。また、参考例1〜4として、GPIIb/IIIa結合剤として知られるヘビ毒タンパク質、エキスタチン(Echistatin)、ならびに、抗血栓症薬であるチロフィバン(Tirofiban;MK383)、ラミフィバン(Lamifiban;Ro44−9883)およびFK633を用いて同様に以下の試験を行った。結果を表1−1〜表1−3に示す。
3×108の血小板/mlを含有する血小板豊富な血漿(PRP)を人血から調製した。225μlのPRPに、試験化合物の水溶液25μlを加え、その後37℃で2分間攪拌した。その溶液に、5μlのADP(最終的には2.5μM)を凝集誘導物質として加えた。凝集をアグリゴメータ(aggregometer)(NBS HEMA−TRACER 801)を用いて測定した。試験手順としては、以下のとおりであった;PRPの光透過度を100%に校正した。PRPをアグリゴメータ内、37℃で2分間インキュベーションした。血小板凝集の完全な応答が得られたときにADPを添加し、光透過率の変化をPL500レコーダー(横河電機社製)によりモニターした。試験化合物の非存在下での凝集との比較により試験化合物の凝集阻害の割合を算出した。誘導物質(試験化合物)の活性をIC50値、すなわち血小板凝集を完全に阻害するのに必要な用量で表した。
試験1の値が小さいほど、活性型GPIIb/IIIaに対する試験化合物の結合性が高いことを表す。
ヒト静脈血を採取し、クエン酸ナトリウムと混合した。全血から遠心分離により血小板豊富な血漿(PRP)を調製した。血小板を1μM PGE1を含む調製HEPES−Tyrodeバッファー(129mM NaCl、2.8mM KCl、0.8mM KH2PO4、8.9mM NaHCO3、0.8mM MgCl2、10mM HEPES、5.5mM グルコース、0.1% BSA、pH7.4)で洗浄した。洗浄後、1.0mM CaCl2、1μM PGE1を含む調製HEPES−Tyrodeバッファーに血小板を懸濁し、血小板の数を調整した。
試験2の値が大きいほど、静止型GPIIb/IIIaに対する試験化合物の結合性が低いことを表す。
結果を、表1−1〜表1−4に示す。
本発明の血栓造影剤に用いるGPIIb/IIIa結合性化合物は、従来技術に示されたADP誘導血小板凝集阻害試験におけるIC50値より低いIC50値を示しており、ADPで活性化された血小板の表面のGPIIb/IIIaに結合することが明らかである。
DMF(10ml)中の(2E)−3−[1−(tert−ブトキシカルボニル)−4−ピペリジニル]アクリル酸(1.6g、6.27mmol)、式:
1H-NMR(300MHz, DMSO-d6) δ; 1.18-1.36(2H, m), 1.49(9H, s), 1.53(18H, s), 1.71-1.84(2H, m), 2.32-2.47(1H, m), 2.74-2.99(2H, m), 3.94-4.11(2H, m), 4.71(2H, d, J=5.5Hz), 4.85(2H, s), 4.91(2H, s), 6.14(1H, d, J=15.4Hz), 6.70(1H, dd, J=15.4, 6.2Hz), 7.09(1H, d, J=8.8Hz), 7.49(1H, d, J=2.2Hz), 7.76(1H, dd, J=8.8, 2.2Hz), 8.36(1H, brt, J=5.5Hz); MS(ES+)m/zは検出されず
1H-NMR(300MHz, DMSO-d6) δ; 0.02-0.08(6H, m), 0.98(9H, s), 1.15-1.30(2H, m), 1.43(9H, s), 1.44(9H, s), 1.46(9H, s), 1.61-1.78(2H, m), 2.27-2.48(1H, m), 2.68-2.91(2H, m), 3.88-4.04(2H, m), 4.70(2H, s), 4.72(2H, s), 6.23(1H, d, J=15.8Hz), 6.71(1H, d, J=6.2Hz), 6.76(1H, d, J=6.2Hz), 6.85-6.94(2H, m), 7.01(1H, dd, J=8.1, 1.8Hz); MS(ES+)m/zは検出されず
製造例15で製造したアセトニトリル(1.5mL)中の化合物(13.0mg,30μmol)の溶液を、[18F]フッ素イオンの溶液に添加した。混合物を85℃で20分間加熱した。室温に冷却後、4M HCl(1.0mL)を添加した。混合物を100℃で10分間加熱した。得られた混合物を、0.1%アセトニトリル−0.05M NH4OAcで溶出するHPLCカラム(YMC−パック C18 Pro、10×250mm、YMC社製)で精製して、[18F]で標識された血栓造影剤を得た。
製造例21で製造した[11C]で標識された血栓造影剤、および製造例22で製造した[18F]で標識された血栓造影剤を用いて、サル(Macca fascicularis)の体内での標識化合物の動向を調べた。
イヌ伏在静脈(足の母指の背側指静脈と足背静脈弓の合流によりつくられ、内果の前方、大腿骨内側顆の後方上行し、大腿広筋膜の伏在裂孔を横切り、大腿三角の上部で大腿静脈に注ぐ)血栓モデル(Knight L. C. et al., Thromb Haemost., 1998; 80: p.845〜851およびLister-James L. et al., J. Nucl Med. 1996; 37: p.775〜781を参照)に従って、麻酔下のサルの右大腿静脈に塞栓形成用プラチナコイル(ボストンサイエンティフィックジャパン社製)を挿入、固定して傷口を縫合した。
結果を以下の表2に示す。データは、パーセント/投与量として計算した(%ID/kg/g)。
また、PETによる撮影では、バックグラウンドノイズが低く、解像度が高い血栓の撮影を行うことが可能であった。
Claims (1)
- 糖タンパク質IIb/IIIa結合性化合物である、式(IV):
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510171A JP4910695B2 (ja) | 2004-02-25 | 2005-01-13 | 血栓造影剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004049996 | 2004-02-25 | ||
JP2004049996 | 2004-02-25 | ||
PCT/JP2005/000308 WO2005079863A1 (ja) | 2004-02-25 | 2005-01-13 | 血栓造影剤 |
JP2006510171A JP4910695B2 (ja) | 2004-02-25 | 2005-01-13 | 血栓造影剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2005079863A1 JPWO2005079863A1 (ja) | 2008-01-10 |
JP4910695B2 true JP4910695B2 (ja) | 2012-04-04 |
Family
ID=34879569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006510171A Expired - Fee Related JP4910695B2 (ja) | 2004-02-25 | 2005-01-13 | 血栓造影剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070189970A1 (ja) |
EP (2) | EP2404899A1 (ja) |
JP (1) | JP4910695B2 (ja) |
CA (1) | CA2558064A1 (ja) |
WO (1) | WO2005079863A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1906990B1 (en) * | 2005-07-05 | 2013-12-11 | Baker Medical Research Institute | Anticoagulation agent |
ES2621379T3 (es) | 2011-08-17 | 2017-07-03 | Piramal Imaging Sa | Compuestos para la unión a la glicoproteína IIb/IIIa específica de las plaquetas y su utilización para la formación de imágenes de trombos |
CA2900595A1 (en) | 2013-02-12 | 2014-08-21 | Bayer Pharma Aktiengesellschaft | Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021599A1 (en) * | 1993-03-17 | 1994-09-29 | Meiji Seika Kabushiki Kaisha | Novel compound with platelet aggregation inhibitor activity |
JPH0853415A (ja) * | 1994-07-11 | 1996-02-27 | Fujisawa Pharmaceut Co Ltd | β−アラニン誘導体およびその製造法 |
JP2000506524A (ja) * | 1996-03-13 | 2000-05-30 | 藤沢薬品工業株式会社 | フィブリノーゲン受容体拮抗剤であるN―[(R)―1―{3―(4―ピペリジル)プロピオニル}―3―ピペリジルカルボニル]―2(S)―アセチルアミノ―β―アラニン |
JP2001504801A (ja) * | 1996-06-10 | 2001-04-10 | ジー.ディー.サール アンド カンパニー | 血栓サイトに局在化可能な放射性医薬組成物 |
JP2003503310A (ja) * | 1999-04-14 | 2003-01-28 | ディアタイド,インコーポレイティド | 血栓造影用ベンゾジアゼピン誘導体 |
JP2003523339A (ja) * | 2000-02-17 | 2003-08-05 | 藤沢薬品工業株式会社 | ベータ−アラニン誘導体および受容体アンタゴニストとしてのそれらの用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084466A (en) * | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
US5726192A (en) * | 1992-12-29 | 1998-03-10 | Smithkline Beecham Corporation | Platelet aggregation inhibiting compounds |
US5879657A (en) * | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
TW401414B (en) | 1993-09-22 | 2000-08-11 | Fujisawa Pharmaceutical Co | <beta>-alanine derivative and a process for the preparation thereof |
US5770575A (en) | 1994-03-16 | 1998-06-23 | Ortho Pharmaceutical Corporation | Nipecotic acid derivatives as antithrombotic compounds |
IL117495A (en) | 1995-03-17 | 2002-05-23 | Fujisawa Pharmaceutical Co | History of b-alanine, the process for their preparation and the pharmaceutical preparations containing them |
AU6332396A (en) * | 1995-06-07 | 1996-12-30 | Centocor Inc. | Platelet-specific chimeric immunoglobulin and methods of use therefor |
AU726594B2 (en) | 1996-05-01 | 2000-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders |
US6066651A (en) | 1997-10-29 | 2000-05-23 | Ortho-Mcneil Pharmaceutical, Inc. | Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders |
AUPP646598A0 (en) | 1998-10-12 | 1998-11-05 | Fujisawa Pharmaceutical Co., Ltd. | New processes for producing alpha-alanine derivative |
AU2001286702B2 (en) * | 2000-08-24 | 2008-03-13 | University Of Pittsburgh | Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease |
JP3991086B2 (ja) * | 2000-12-23 | 2007-10-17 | ダイアックス、コープ | 造影剤として有用なフィブリン結合部分 |
-
2005
- 2005-01-13 US US10/590,295 patent/US20070189970A1/en not_active Abandoned
- 2005-01-13 EP EP11184147A patent/EP2404899A1/en not_active Withdrawn
- 2005-01-13 EP EP05703547A patent/EP1719529A4/en not_active Withdrawn
- 2005-01-13 WO PCT/JP2005/000308 patent/WO2005079863A1/ja active Application Filing
- 2005-01-13 CA CA002558064A patent/CA2558064A1/en not_active Abandoned
- 2005-01-13 JP JP2006510171A patent/JP4910695B2/ja not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021599A1 (en) * | 1993-03-17 | 1994-09-29 | Meiji Seika Kabushiki Kaisha | Novel compound with platelet aggregation inhibitor activity |
JPH0853415A (ja) * | 1994-07-11 | 1996-02-27 | Fujisawa Pharmaceut Co Ltd | β−アラニン誘導体およびその製造法 |
JP2000506524A (ja) * | 1996-03-13 | 2000-05-30 | 藤沢薬品工業株式会社 | フィブリノーゲン受容体拮抗剤であるN―[(R)―1―{3―(4―ピペリジル)プロピオニル}―3―ピペリジルカルボニル]―2(S)―アセチルアミノ―β―アラニン |
JP2001504801A (ja) * | 1996-06-10 | 2001-04-10 | ジー.ディー.サール アンド カンパニー | 血栓サイトに局在化可能な放射性医薬組成物 |
JP2003503310A (ja) * | 1999-04-14 | 2003-01-28 | ディアタイド,インコーポレイティド | 血栓造影用ベンゾジアゼピン誘導体 |
JP2003523339A (ja) * | 2000-02-17 | 2003-08-05 | 藤沢薬品工業株式会社 | ベータ−アラニン誘導体および受容体アンタゴニストとしてのそれらの用途 |
Also Published As
Publication number | Publication date |
---|---|
EP1719529A4 (en) | 2008-05-21 |
WO2005079863A1 (ja) | 2005-09-01 |
EP1719529A1 (en) | 2006-11-08 |
JPWO2005079863A1 (ja) | 2008-01-10 |
EP2404899A1 (en) | 2012-01-11 |
US20070189970A1 (en) | 2007-08-16 |
CA2558064A1 (en) | 2005-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101948362B1 (ko) | 혈소판 특이적 당단백질 iib/iiia에 결합하는 화합물 및 혈전의 영상화를 위한 그의 용도 | |
ES2348829T3 (es) | Benzimidazol-2-il-pirimidinas y pirazinas moduladoras del receptor h4 de histamina. | |
JP4220897B2 (ja) | ピペラジン化合物 | |
ES2384002T3 (es) | Agentes radioactivos para la obtención in vivo de imágenes PET de CCR5 | |
PL178252B1 (pl) | Nowe cykliczne pochodne aminokwasowe i nowe znakowane cykliczne pochodne aminokwasowe | |
RU2194038C2 (ru) | Карбоксамидные производные пирролидина или пиперидина, фармацевтическая композиция на их основе и способ ингибирования агрегации тромбоцитов | |
JP6164556B2 (ja) | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 | |
CN102203061A (zh) | 选择性seprase抑制剂 | |
KR20060123415A (ko) | 신규한 m3 무스카린성 아세틸콜린 수용체 길항제 | |
JP4910695B2 (ja) | 血栓造影剤 | |
KR20200081445A (ko) | 허혈성 졸중의 치료를 위한 방향족 술폰아미드 유도체 | |
HUT74871A (en) | Nipecotic acid derivatives as antithrombic compounds | |
JP2002527450A (ja) | 画像形成試薬としてのキレーターが組み込まれたArg−Gly−Asp(RGD)ミメティック合成ディスインテグリン類 | |
ES2248737T3 (es) | Compuestos 1-(d-ciclopropilglicinil)-4-(piperidin-4-il)piperazina como inhibidores del factor xa de la serina proteasa. | |
CN111655686B (zh) | 四氢异喹啉类衍生物及其制备方法和用途 | |
WO1995001336A1 (fr) | Nouveau derive de piperidine | |
SK152001A3 (en) | Bispiperidines as antithrombotic agents | |
KR100251622B1 (ko) | 피브리노겐 수용체 길항물질 및 전기물질을 유효성분으로 하는 의약제제 | |
KR20210121959A (ko) | 혈전영상을 위한 방사성의약품 및 조성물 | |
JP2001002664A (ja) | アラニン誘導体 | |
WO2015121163A1 (en) | Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia | |
JPH08333341A (ja) | 新規なピペラジン誘導体又はその塩 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071213 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110411 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111118 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20111129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111220 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120102 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150127 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150127 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150127 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150127 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |